Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Amgen, Inc and Servier Pharmaceuticals LLC.

Cancer Summaries and Commentaries®: Updates in the Treatment of Hematologic Malignancies from Chicago, Amsterdam, and Barcelona

Release Date: May 15, 2020
Expiration Date: May 15, 2021

Activity Overview

This online activity is designed to update clinicians on data presented at 3 noteworthy meetings: the 24th European Hematology Association Congress (EHA 2019), held June 13 to 16, 2019, in Amsterdam, The Netherlands; the American Society of Clinical Oncology Annual Meeting, held May 31 to June 4, 2019, in Chicago, Illinois; and the European Society for Medical Oncology Congress 2019 (ESMO 2019), held September 27 to October 1, 2019, in Barcelona, Spain. This activity will help facilitate critical assessment and clinical integration of new evidence, when appropriate, and reviews 8 abstracts that focus on the treatment of hematologic malignancies. For each abstract, a text summary of key clinical data is accompanied by perspectives from expert thought leaders who provide insights into how clinicians can apply these findings to their clinical practice to improve patient care.

Acknowledgement of Support

This activity is supported by educational grants from Amgen, Inc and Servier Pharmaceuticals LLC.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists and hematologists involved in the treatment and management of patients with cancer.

Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals (HCPs) interested in the treatment of cancer may also participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Discuss recent evidence concerning the efficacy and safety of emerging agents under clinical investigation for hematologic malignancies
  • Integrate recent findings from trials in hematologic malignancies into evolving treatment paradigms
  • Consider best practices to proactively mitigate and manage treatment-related adverse events in patients with hematologic malignancies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Hetty Carraway, MD, MBA
Hetty Carraway, MD, MBA
Vice Chair, Strategy and Enterprise Development
Taussig Cancer Center
Cleveland Clinic
Associate Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH

Disclosures: Grant/Research Support: Celgene Corp – clinical trial support; Consultant: Agios Pharmaceuticals Inc, Bristol Myers Squibb Co, and Daiichi Sankyo Co Ltd; Speaker’s Bureau: Stemline Therapeutics Inc, Agios Pharmaceuticals Inc, Celgene Corp, Bristol Myers Squibb Co, Novartis AG, and Jazz Pharmaceuticals Inc; Other support: Independent Review Committee – Takeda Pharmaceutical Co Ltd, AbbVie Inc, and ASTEX Pharmaceuticals.

Daniel J. DeAngelo, MD, PhD
Daniel J. DeAngelo, MD, PhD
Chief of the Division of Leukemia, Institute Physician
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: AbbVie Inc, GlycoMimetics Inc, Novartis AG, and Blueprint Medicines Corp; Consultant: Amgen Inc, Autolus Therapeutics Ltd, Blueprint Medicines Corp, Celgene Corp, Incyte Corp, Jazz Pharmaceuticals Inc, Novartis AG, Pfizer Inc, Shire, and Takeda Pharmaceutical Co Ltd.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By